diabetes: a randomised, open-label, non-inferiority study. Lancet 372 (9645): 1240-1250.
33. Forti A, Garcia EG, Yu MB, Jimenez MC, Brodows RG, Oliveira JH (2008) Efficacy and safety of exenatide administered before the two largest daily meals of Latin American patients with type 2 diabetes. Curr Med Res Opin 24 (9): 2437-2447.
34. Nyström T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahrén B, et al (2004) Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 287: E1209-E1215.
35. Thrainsdottir I, Malmberg K, Olsson A, Gutniak M, Rydén L (2004) Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure. Diab Vasc Dis Res 1: 40-43.
36. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP (2006) Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 12: 694-699.
37. Bunck MC, Diamant M, Eliasson B, Cornér A, Shaginian RM, Heine RJ, et al (2010) Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care 33 (8): 1734-1737.
38. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008; 24(10): 2943-2952.
39. Ficha técnica de Byetta. Última ficha técnica aprobada.